These data are consistent with our previously published work that treatment with vascular endothelial growth factor A165b and angiopoietin-1 reversed damage to the glomerular endothelial glycocalyx and normalized glomerular permeability in early DKD.24 Here, VEGFA is linked to diabetic kidney disease.